Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NQO1 | P15559 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25384205 | 0.86 | TP53 (0.53) | KDM4ETSHRTP53CYP3A4ALDH1A1 | |
| SCHEMBL10448057 | 0.86 | KDM4E (0.60) | KDM4ETSHRTP53CYP3A4ALDH1A1 | |
| SCHEMBL146850 | 0.85 | TP53 (0.56) | KDM4ETSHRTP53CYP3A4ALDH1A1 | |
| SCHEMBL4280414 | 0.85 | TP53 (0.56) | KDM4ETSHRTP53CYP3A4ALDH1A1 | |
| SCHEMBL5018851 | 0.85 | KDM4E (0.69) | KDM4ETSHRALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL8045881 | 0.85 | TP53 (0.52) | KDM4ETSHRTP53CYP3A4ALDH1A1 | |
| SCHEMBL6055352 | 0.85 | TP53 (0.52) | KDM4ETSHRTP53CYP3A4ALDH1A1 | |
| SCHEMBL16953912 | 0.85 | TP53 (0.52) | KDM4ETSHRTP53CYP3A4ALDH1A1 | |
| SCHEMBL7640732 | 0.85 | TP53 (0.56) | KDM4ETSHRTP53CYP3A4ALDH1A1 | |
| SCHEMBL14200522 | 0.84 | KDM4E (0.63) | KDM4ETSHRALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976061-B2 | Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | Merck Sharp & Dohme, LLC (US) | 2024-05-07 | — | — | US | disclosed |
| US-11976061-B2 | Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | Merck Sharp & Dohme, LLC (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORPORATION | 2024-02-29 | — | — | US | disclosed |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORPORATION | 2024-02-29 | — | — | US | disclosed |
| US-11787810-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | PROMEGA CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | PROMEGA CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| EP-0857067-A4 | RADIOPROTECTORS | PETER MACCALLUM CANCER INST (AU) | 2005-01-19 | — | — | EP | disclosed |
| US-6548505-B1 | Protecting biological materials from damage caused by radiation; side effect reduction during radiotherapy or chemotherapy; indole, benzimidazole, benzoxazole or benzothiazole compounds substituted with 4-alkylpiperazino | PETER MACCALLUM CANCER INSTITUTE (AU) | 2003-04-15 | — | — | US | disclosed |
| US-6194414-B1 | CANCER THERAPY; PREVENT RADIATION DAMAGE | THE INNER AND EASTERN HEALTH CARE NETWORK (AU) | 2001-02-27 | — | — | US | disclosed |
| EP-0857067-A1 | RADIOPROTECTORS | The Inner and Eastern Health Care Network (AU) | 1998-08-12 | — | — | EP | disclosed |
| WO-1997004776-A1 | RADIOPROTECTORS | THE INNER AND EASTERN HEALTH CARE NETWORK (AU) | 1997-02-13 | — | — | WO | disclosed |
| US-4257926-A | SIMULTANEOUSLY WITH VULCANIZATION USING A COPOLYCONDENSATE OF A PHENOL, FORMALDEHYDE AND RESORCINOL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | KDM4E 2459/4885TSHR 2599/4885TP53 167/4885 |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | CYP4Z1, CYP2E1, CYP2F1 | KDM4E 2418/4885TSHR 2957/4885TP53 2233/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | KDM4E 1618/4885TSHR 2250/4885TP53 1637/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | KDM4E 2973/4885TSHR 1187/4885TP53 4503/4885 |
| US-11787810-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | KDM4E 2205/4885TSHR 4648/4885TP53 2759/4885 |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PGLS, AADAC, GLB1 | KDM4E 4319/4885TSHR 3586/4885TP53 2544/4885 |
| US-11976061-B2 | Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | KDM4E 1773/4885TSHR 4673/4885TP53 3181/4885 |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | KDM4E 2164/4885TSHR 780/4885TP53 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.